Cardiometabolic outcomes of early onset hypogonadism in males.

Testosterone is characterized as an important vascular hormone with multiple effects on the vasculature.

• The review frames testosterone's vascular role as central to understanding cardiometabolic risk in hypogonadism.
• Cardiovascular changes in the young are noted to affect future cardiovascular health.
• The paper situates testosterone supplementation effects in adults as context for understanding early onset hypogonadism.

Boys and men with early onset hypogonadism may have altered cardiovascular function with potential for adverse cardiometabolic outcomes in adulthood.

• Conditions specifically highlighted include 46,XY Disorders of Sex Development (DSD) and Klinefelter Syndrome.
• The review distinguishes early onset hypogonadism from adult-onset hypogonadism in terms of cardiovascular impact.
• The paper reviews both what is known about adult hypogonadism and what is currently understood in early onset hypogonadism specifically.

There is a need to better understand the influence of androgens on the vasculature in individuals with conditions causing early onset hypogonadism.

• The review identifies 46,XY Disorders of Sex Development and Klinefelter Syndrome as key conditions of interest.
• The paper summarizes existing knowledge about hypogonadism and testosterone supplementation effects in adults.
• Current understanding in those with early onset hypogonadism specifically is noted to be limited.

A number of research gaps persist in the area of early onset hypogonadism and cardiometabolic outcomes.

• The review explicitly identifies persisting research gaps in this area.
• The authors call for international collaborative studies to address these gaps.
• The stated purpose is to improve outcomes 'for future generations of affected individuals.'